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Objectives: This study aimed to investigate the correlation between cardiovascular 
(CV) health and CV disease knowledge of Life’s Simple 7 (LS7) among 3 age groups in 
Hong Kong – young adults, middle aged, and the elderly. MethOds: Young adults 
and middle-aged adults were identified from the on-campus health check at the 
Chinese University of Hong Kong. Elderly subjects were recruited from the com-
munity outreach in 15 community elderly centers. The subjects’ demographics, 
lifestyle behavior and risk knowledge were obtained through a validated question-
naire. The body mass index, random capillary blood glucose, blood cholesterol and 
blood pressure were measured during the on-campus health check and community 
outreach sessions. LS7 score and risk knowledge score for each subject were calcu-
lated. Logistic regression was used to estimate the odd ration and 95% confidence 
intervals for the demographic characteristics on LS7 and knowledge. Results: A 
total of 996 subjects were included in this study (mean age: 56.3 ± 25.5 years old; 28% 
male). There were only 0.6% subjects had ideal CV health while 35.9% had 5 to 7 ideal 
CV health metrics. Subjects ≥ 65 years (OR 2.341, 95% CI 1.779-3.080, P < 0.0005) and 
subjects with tertiary education or above (OR 2.031, 95% CI 1.527-2.701, P < 0.0005) 
were more likely to obtain optimum LS7 (scoring ≥ 10 out of 14 in LS7 score). Subjects 
≤ 65 years (OR 1.695, 95% CI 1.297-2.215, P < 0.0005) and those with tertiary education 
or above (OR 1.859, 95% CI 1.412-2.448, P < 0.0005) were more likely to obtain full CV 
disease risk knowledge score. No association was found between having optimum 
LS7 and full CV knowledge. cOnclusiOns: Less than 1% of adults in this study 
population had ideal CV health as defined by AHA. Knowledge has no association 
but young age and tertiary education had positive association with CV health.
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Objectives: Genotype-guided therapy has been demonstrated to enhance the accu-
racy of warfarin dosing. However, factors that limit the predictive accuracy of this 
approach have not been evaluated in a heterogeneous population. This study identi-
fied patient characteristics and clinical factors that contributed to poor prediction of 
a warfarin therapeutic dose when using a genotyped-guided approach. MethOds: 
This was a prospective observational study of patients managed by the University of 
Illinois Hospital and Health Sciences System Pharmacogenetics Service who have 
attained a warfarin therapeutic dose. The primary outcome was a large dose devia-
tion (> 20%) between the genotype-guided predicted dose and the actual warfarin 
therapeutic dose. Variables examined included patient demographics, interacting 
medications, comorbidities, genotype information, baseline international normal-
ized ratio, and reason for anticoagulation. Multivariate logistic regression was used 
to estimate the odds ratio (OR) for a large dose deviation. Results: Of the 146 
consecutive patients enrolled, 23.3% were Hispanics, 54.1% were African American, 
and the mean age was 54.2±17.9 years. Fifty-three percent of the study cohort had a 
large dose deviation. After adjusting for potential confounders, being middle aged 
(41-65 vs. 18-40 years) and Hispanic (vs. Whites and Asians) had a 4.15-fold (95%CI 
1.24-13.95, p= 0.021) and 7.58-fold (95%CI 1.69-33.93, p= 0.008) increased odds for 
a large dose deviation, respectively. Patients who took warfarin for thrombosis 
prophylaxis versus treatment were 3.2-fold more likely to have a large dose devia-
tion (95%CI 1.14-8.99, p= 0.027). In addition, patients who required a high warfarin 
maintenance dose (> 7.5mg/day) versus average dose (3-7.5 mg/day) were at an 
elevated risk (adjusted OR 5.21, 95%CI 1.30-20.78, p= 0.019) of having a large dose 
deviation. cOnclusiOns: Our results highlight factors that might contribute to 
poor prediction of warfarin dosing using a genotype-guided approach and sug-
gest that methods to refine dose prediction are needed for under-studied patient 
populations, including Hispanics and patients receiving warfarin for thrombosis 
prophylaxis.
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Objectives: Elevated low density lipoprotein cholesterol (LDL-C) and low high 
density lipoprotein cholesterol (HDL-C) level is a characteristic of dyslipidemia. 
Increase in blood lipids levels has the potential to cause hepatic disorders such as 
non-alcoholic fatty liver disease and liver cirrhosis. The goal of this study was to 
examine the association between liver enzymes and lipid levels amongst adults 
in the United States. MethOds: The National Health and Nutrition Examination 
Survey (NHANES) data from 2005 to 2006 was used to examine the association 
between liver enzymes and lipid levels amongst adults in the United States. Data 
were analyzed for descriptive statistics and for differences using the t-test, Chi 
square test and ANOVA. A regression analysis was performed to identify relation-
ships between demographic characteristics, liver enzymes and lipid levels. A p value 
of < 0.05 was considered statistically significant. Results: A total of 2,201 adults 
(20 yrs. and above) were included in this study. Sample mean age was 48 ± 19 yrs. 
Thirty eight percent adults had LDL-C levels greater than 130mg/dL and 14% had 
HDL-C levels greater than 60mg/dL according to National Cholesterol Education 
Program - Adult Treatment Panel (NCEP-ATP III) guidelines. A significant relation-
ship was observed between HDL-C and alkaline phosphotase levels (ALP), LDL-C 
and asparatate aminotransferase (AST), triglycerides and AST levels (p< 0.05). Adults 
with LDL-C > 100mg/dL were associated with two times higher odds of abnormal 
AST levels (95%CI:1.5–2.8, p< 0.001), whereas, HDL-C levels < 60 mg/dL were associ-
ated with 2.9 times higher odds of abnormal AST levels (95%CI:2.2–3.7, p< 0.001). 
Regression analysis showed significant relationship between LDL-C, HDL-C, tri-
glycerides, ALT, AST, ALP and age (p< 0.05). cOnclusiOns: There was significant 
association between abnormal asparatate aminotransferase and low HDL-C levels, 
even though low HDL-C levels are desirable to reduce cardiovascular risks. There 
of hypertension in 2008 varied by country (US= 15.6%, UK= 23.4%, Australia= 18.2%, 
Canada= 15.3%, and Saudi Arabia= 31.2%). There were 138 antihypertensive medica-
tions and 61 combinations available in all five countries. The US had the highest 
number of antihypertensive medications (70.0%), followed by Canada (56.5%), UK 
(52.8%), Australia (51.44%) and Saudi Arabia (49.2%). There were 31 combinations 
of antihypertensive medications with the FDA listing 50.8% of those combinations, 
followed by the UK (40.9%), Saudi Arabia and Australia (both 37.7%), and Canada 
(34.4%).The therapeutic classes with the larger number of approvals were beta 
blockers (n= 14), angiotensin-converting enzyme inhibitors (n= 11) and thiazide 
diuretics (n= 11). The relationship between the number of antihypertensive drugs 
approved and hypertension prevalence appeared inverse, (Spearman correlation 
coefficient= -0.8), yet non-significant (P= 0.10), most likely due to lack of power 
(n= 5) and the ecological nature of this correlation. cOnclusiOns: Differences exist 
in the number of antihypertensive medications and therapeutic classes available 
in each country. The US had the highest access to antihypertensive medications 
among the countries included in the study. Further studies are needed to assess 
the utilization of antihypertensive medications and the potential relationship with 
hypertension prevalence.
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Objectives: Although the number of patients with PAH who were certified as 
patients of Specified Rare and Intractable Diseases is annually provided by the 
Ministry of Health, Labor and Welfare (MHLW) in Japan, the morbidity rate and 
treatment situation for PAH has not been clearly investigated yet. This study aimed 
to investigate morbidity rate of PAH using a Japanese healthcare database. The 
pharmaceutical intervention for PAH was also investigated among those with 
PAH. MethOds: The Japanese healthcare database which contains approximately 
2.1 million subjects covered by employment-based health insurance (MinaCare Co. 
Ltd) was used for this study. The patients with PAH who were newly diagnosed 
as Pulmonary Hypertension (PH) between September 1, 2011 and August 31, 2012 
and prescribed at least 1 anti-PAH drug was extracted. The patients with PH were 
identified by using International Classification of Diseases (ICD)-10 codes (I270, I271, 
I272, I278, I279 and P293) or by free formatdiagnosis name including “Pulmonary 
Hypertension”. Results: Of approximately 1.1 million person-years of observation, 
34 were identified as newly diagnosed PAH patients. Therefore, the crude rate of PAH 
morbidity was 30.4 per 1,000,000 person-years. The commonly used medication as 
the first treatment among these 34 patients were Beraprost(70.6%), Sildenafil(20.6%), 
Tadalafil(5.9%) and Bosentan(5.9%). cOnclusiOns: This is the first report to show 
the morbidity rate of PAH in Japan. This study revealed that Beraprost was the most 
commonly used first PAH treatment agent in Japan in the real-world data setting, 
although Sildenafil and Bosentan are recommended to be used as the 1st line treat-
ment in the Guideline for “Treatment of Pulmonary Hypertension” (JCS2012). In 
order to improve the quality of PAH treatment and the patients’ outcome, it is highly 
important to increase awareness of the recommended treatment and fill the gap 
between the guideline and actual clinical use of these drugs.
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Objectives: Inflammation contributes to the pathogenesis of both psoriasis 
and arrhythmia, and psoriasis has been shown to be associated with substantial 
cardiovascular morbidity and mortality. On the other hand, however, only a few 
small studies have investigated the risk of arrhythmia in psoriasis. The aim of this 
study was to determine whether patients with psoriasis have an increased risk of 
arrhythmia. MethOds: A retrospective, population-based matched cohort study 
of patients with psoriasis was conducted from January 1, 2003, to December 31, 
2011. New-onset psoriasis patients (n= 40637) and psoriasis-free matched controls 
(n= 162548) were followed, with a mean follow-up of 6.41 years. Diagnoses and 
prescriptions of the patients were obtained from the National Health Insurance 
Research Database (NHIRD), Taiwan. Patients with psoriasis were classified as severe 
if they received a systemic antipsoriatic therapy and/or phototherapy or otherwise, 
mild. Risk of arrhythmia was analyzed by using a multivariable Cox proportional 
hazards regression model. Results: There were 3910 arrhythmia (9.62%) within the 
psoriasis patients and 11612 (7.14%) arrhythmia within the comparison subjects, 
and the incidences per 100000 person-years were 1541.37 and 1106.09, respectively. 
After adjusted for comorbidities and medications, the incidence risk of arrhythmia 
was increased in all groups of psoriasis patients compared to the controls. The 
adjusted hazard ratios (95% confidence intervals) for arrhythmia were 1.30 (1.25 to 
1.35), 1.31 (1.25 to 1.36), 1.21 (1.09 to 1.34), 1.37(1.16 to 1.62) and 1.29 (1.24-1.34) in the 
overall, mild, severe psoriasis, psoriasis patient with psoriatic arthritis (PsA), and 
psoriasis patients without PsA (PsC), respectively. cOnclusiOns: Patients with 
psoriasis have a higher risk of developing arrhythmia, independent of traditional 
cardiovascular risk factors. Moreover, the risk of arrhythmia in PsA was higher than 
PsC. Increased awareness of the arrhythmia risk in the cardiovascular assessment 
in psoriasis patients is recommended.
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with maternal hypertension. Early diagnosis and treatment through regular ante-
natal check-up is a key factor to prevent PIH and its complications. Interventions to 
improve maternal health through information, education and counselling of women 
of child bearing age should be implemented.
CardioVasCular disorders – Cost studies
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Objectives: Increased perioperative blood pressure (BP) variability in cardiac sur-
gery is associated with negative clinical outcomes and increased health resource 
utilization (HRU). Clevidipine, an ultrashort-acting, arterial selective calcium chan-
nel blocker reduces BP variability and may reduce HRU in this setting. The current 
model evaluates the one year budget impact of adding clevidipine to an intrave-
nous antihypertensive (IVAH) treatment mix in a sample US hospital. MethOds: 
A spreadsheet model was developed using treatment specific HRU data from a 
clevidipine clinical trial (ECLIPSE) in cardiac surgery. Treatment distribution for 
IVAH agents (clevidipine, nicardipine, nitroglycerin, and nitroprusside), case vol-
umes and comparable IVAH dosages were obtained from the Premier Hospital 
database. Unit costs for IVAH are US Wholesale Acquisition Costs (WAC). Thirty-
day event costs were from the published literature. The model inputs may be 
customized to more accurately represent a given healthcare system. Results: 
The base case assumed a sample hospital with 468 coronary artery bypass graft 
(CABG) cases and 322 heart valve (HV) cases annually. Clevidipine usage in the 
base case was minimal (0% in CABG; 1% in HV). The base case predicts a one year 
total cost of $19,045,453 with the largest proportion of costs from general ward, 
ICU and operative suite time (approx. 30%, 21%, and 20% respectively). One year 
IVAH costs totaled $93,958 or 0.5% of total costs. Increasing the proportion of cases 
receiving clevidipine to 5% for both procedures increased drug acquisition costs 
by $13,005 and decreased HRU-related costs by $48,439 for a net decrease in costs 
of $35,434 for one year. cOnclusiOns: This analysis predicts a net savings with 
an increase in clevidipine use. In this example case, a minimal increase in IVAH 
costs was offset by savings in HRU-related costs resulting from improved outcomes 
associated with reduced perioperative BP variability.
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Objectives: To construct a budget impact model (BIM) to evaluate the economic 
impact of a combination of 5% albumin and crystalloids compared to crystalloids 
alone as fluid therapy administered to patients within one day of undergoing on-
pump coronary artery bypass graft (CABG) and/or valve procedures. MethOds: 
Model parameters were obtained from clinical outcomes determined from a pro-
pensity-matched retrospective US electronic health record (EHR) database (Health 
Facts, Cerner) analysis performed to assess the differences in patient outcomes 
for those who received albumin and crystalloid solutions versus crystalloids alone 
for fluid therapy post cardiac surgery. The BIM was developed to evaluate the eco-
nomic impact of increased usage of 5% albumin for volume therapy within one 
day of undergoing on-pump cardiac surgery. The model utilizes economic costs for 
treating complications obtained from published literature and reports as well as 
data from the EHR database analysis. The BIM covers a 2-year period and presents 
annual and cumulative costs from both a total hospital and total pharmacy perspec-
tive. Results: A base case analysis for a hospital performing 100 cardiac surgeries 
per month results in a 2-yr cumulative savings of $1.32MM, assuming that 70% 
of patients require fluid resuscitation. The increased fluids cost associated with 
increased 5% albumin utilization is offset by reduced costs in hospital readmissions 
and treating fewer complications of pneumonia, acute kidney injury (AKIN stage 
III) and electrolyte abnormalities. In-hospital mortality was significantly lower in 
patients receiving 5% albumin (2.4% vs. 4.1% for crystalloids alone, p= 0.02) which is 
reported strictly as a clinical outcome within the model. cOnclusiOns: There are 
both clinical and economic advantages associated with increased utilization of 5% 
albumin for fluid therapy in patients following on-pump cardiac surgery. Hospital 
analysis of cardiac procedure outcomes and economics is particularly relevant given 
recent CMS value-based purchasing initiatives.
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Objectives: To estimate the expected cost of the pharmacological treatment 
on prevalence of arterial hypertension (AH), diabetes mellitus (DM) and dyslipi-
demia in the Chilean population, following the recent approval of Drug National 
Funds. MethOds: The drugs considered in this study and the information about it, 
were obtained through a review of clinical guideline or technical norms published by 
the health ministery of Chile. The cost was estimated using the drug consumption 
patterns from the national health survey 2009-2010 and from a vector of prices for 
every drug and their combination of uses, for both public and private health sys-
tems through the public market platform and IMS health Chile. 10.000 Montecarlo 
could be a potential link between lipid metabolism and liver diseases, which neces-
sitate further investigation.
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Objectives: Studies have shown that statins may induce diabetes in non-diabetic 
cardiovascular disease patients, as class effect. It is uncertain if any particular statin 
is more likely to have greater risk of developing diabetes; only direct and indirect 
comparison of treatment effects may clarify this uncertainty. We had previously con-
ducted a systematic literature review to estimate the relative likelihood of statin vs. 
placebo or other agents. This network meta-analysis (NMA) was conducted to rank 
the treatments according to their risk of developing diabetes. MethOds: We searched 
databases like Embase, PubMed, and Cochrane. Randomized controlled trials that 
studied one of the statins and reported incidence of diabetes as an outcome were 
considered for inclusion. Data synthesis was performed by pairwise meta-analysis 
and NMA using STATA® with routines available from www.mtm.uoi.gr. Results: 
Twelve trials were included in this review, in which 78,677 participants had been 
randomized. The follow-up ranged from two to nine years among the studies. As 
previously reported the pair-wise meta-analysis showed that statins significantly 
increased the odds of developing diabetes compared to placebo without considerable 
heterogeneity [OR 1.15; 95% CI 1.06, 1.25; p= 0.0006; I250%]. From the present NMA, the 
drug with highest odds for developing diabetes was simvastatin 80mg [OR 5.24; 95% 
credible intervals (CrI) 1.28, 21.46], followed by simvastatin 20mg [OR 4.89; 95% CrI 
1.20, 19.91], atorvastatin 80mg [OR 1.29; 95% CrI 1.00, 1.67], rosuvastatin [OR: 1.22, 95% 
CrI 1.05, 1.43] compared to placebo. Atorvastatin 10mg and pravastatin did not signifi-
cantly increase the risk of diabetes in the network meta-analysis. cOnclusiOns: 
To the best of our knowledge, this is the first study exploring this correlation. The 
NMA shows the risk of developing diabetes to be higher with simvastatin. However, 
this should be confirmed from observational studies using a large safety database.
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Objectives: To assess in a community setting the clinical characteristics, the out-
comes and the related costs of patients admitted for an acute coronary syndrome 
(ACS) or a stroke/TIA (CVD) or a peripheral artery disease (PAD). MethOds: From the 
ARNO Observatory, we carried out a record linkage analysis of discharge records for 
ACS and prescription databases, which included 2,989,512 subjects of 7 Local Health 
Authorities from Northern to Southern Italy. The accrual period lasted from January 
1 to December 31, 2011. Results: Of the 2,989,512 subjects, 6,226 (2.1‰) were hos-
pitalized for ACS, 9,939 (3.3‰) for a CVD and 1,048 (0.4‰) for PAD. Patients admitted 
for CVD were significantly older and of female gender than patients with ACS or PAD 
(age 75 ± 13 vs 71 ± 13 vs 73 ± 11, p< 0.001) (gender 50.6% vs 35.5% vs 31.9%, p < 0.001). 
In-hospital mortality rate was 6.9%, 4.6% and 1.0% (p< 0.001) respectively for CVD, 
ACS and PAD. Over the 1-year follow-up, 63.3% of the patients with ACS needed to be 
readmitted again vs 49.1 of those with CVD and 57.6% of PAD. The average yearly cost 
per patient for the ACS population was 16,897€ /year (drugs, 1,692€ ; hospitalizations, 
14,198€ ; diagnostic and outpatient visits, 1,007€ ), for the CVD 10,440€ /year (drugs, 
1,135€ ; hospitalizations, 8,745€ ; diagnostic and outpatient visits, 560€ ) and for PAD 
14,872€ /year (drugs, 1,649€ ; hospitalizations, 11,781€ ; diagnostic and outpatient vis-
its, 1,442€ ). cOnclusiOns: In a large and representative community setting, CVD 
patients have a worse in-hospital outcome than patients with ACS or PAD. However, 
the costs for the NHS were higher for patients with ACS or PAD being the main cost 
driver the need for further readmissions during the follow-up period.
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Objectives: The objective of this thesis is to study and evaluate the Dug utiliza-
tion pattern and clinical outcome in pregnancy induced hypertension in tertiary 
care hospitals. MethOds: This Retrospective observational study was carried 
out in department of obstetrics and gynecology, CKM and Vishwas hospital, S.V.R. 
Hospital, warangal. Data were collected as per inclusion and exclusion criteria 
and analyzed for drug utilization pattern of antihypertensive drugs with their 
teratogenic risk category as well as for WHO drug use indicators at initiation and 
during entire study period. Neonatal morbidity and mortality outcome was also 
assessed. Results: Out of the 165 total prescriptions studied majority were in age 
group 21-25years,illiterates and low income group. The most commonly prescribed 
antihypertensive Monotherapy was Methyldopa (35.1%) followed by Nifedipine 
(18.78%). Labetolol and Nifedipine combination was most commonly used multi 
drug regimen(9.69%). Majority drugs prescribed were from category B and C. Average 
number of drugs per prescription are five. Single drug therapy was prescribed in 
72.21 % patients.50% of the drugs are from WHO essential drug list of 18th edition. 
The most common neonatal outcome was low birth weight (84.88%), followed by 
fetal distress (9.30%), neonatal deaths(3.48%) and IUGR(2.32%).A significant correla-
tion was found between Diastolic blood pressure of mother and neonatal morbidity 
and mortality rate. cOnclusiOns: Methyldopa was the commonly prescribed anti-
hypertensive in monotherapy as well as combination for PIH. This necessitates the 
development, implementation, and evaluation of policies on the use of antihyper-
tensive drugs. The incidence of high neonatal morbidity and mortality is associated 
